Zenas Biopharma (NASDAQ:ZBIO – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Tuesday, March 25th. Analysts expect Zenas Biopharma to post earnings of ($0.92) per share for the quarter.
Zenas Biopharma Stock Down 2.2 %
Shares of NASDAQ:ZBIO opened at $8.33 on Monday. Zenas Biopharma has a 1-year low of $5.83 and a 1-year high of $26.25. The firm has a market cap of $348.19 million and a PE ratio of -2.35.
Wall Street Analysts Forecast Growth
ZBIO has been the topic of several recent analyst reports. Wedbush initiated coverage on Zenas Biopharma in a research report on Thursday. They set an “outperform” rating and a $35.00 price objective on the stock. Guggenheim reaffirmed a “buy” rating and set a $45.00 price objective on shares of Zenas Biopharma in a research report on Wednesday, March 12th.
About Zenas Biopharma
Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
See Also
- Five stocks we like better than Zenas Biopharma
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
- How to Profit From Value Investing
- 3 ETFs to Ride the VIX Surge During Market Volatility
- Why Invest in High-Yield Dividend Stocks?
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
Receive News & Ratings for Zenas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zenas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
